SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its ongoing holiday sweepstakes, which is generating widespread community discussion and mixed reactions. Many users are expressing disappointment over receiving small crypto prizes, such as Solana or Dogecoin, and are complaining about app glitches during the prize reveal. This has led to skepticism and criticism regarding the promotion's value and execution, contrasting with a few users claiming significant wins.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is experiencing significant market attention following promising preliminary Phase 3 trial data, which indicated an 80% reduction in breast cancer recurrence rates. This, coupled with the Board's decision to extend share lock-ups for directors and officers until September 2026, signals strong insider confidence and further fuels discussions among investors. The community is actively debating the stock's low float and high cost to borrow, anticipating a potential short squeeze as long-term holders express conviction in the therapy's market potential.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical ($RARE) is trending following a significant sell-off after its brittle-bone disease drug, setrusumab, failed to meet the primary endpoint in late-stage trials. This unexpected outcome, despite positive secondary data, has sparked intense community debate, with some viewing the dramatic price drop and massive volume as an overreaction and a buying opportunity given the company's other approved products and pipeline. Conversely, others point to fundamental balance sheet concerns and pre-announcement insider selling as justification for the decline.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. is a trending topic due to an exceptionally high short borrow rate, exceeding 400%, and an extremely tight float with zero shares available, sparking widespread community speculation about a significant short squeeze. The stock's position in the hot space sector, alongside anticipation for FAA approval and broader industry growth potentially ignited by future major IPOs like SpaceX, is also driving investor conversation.

DigitalBridge Group, Inc. is a global alternative asset manager, which engages in investing in digital infrastructure. The firm focuses on operating businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure. It operates through the following segments: Investment Management, Operating, and Corporate and Other. The Investment Management segment represents the global investment management platform, deploying, and managing capital on behalf of a diverse base of global institutional investors. The Operating segment refers to the digital infrastructure and real estate operating companies, which generally earn rental income from providing use of digital asset space and capacity through leases, services, and other agreements. The Corporate and Other segment includes investment and corporate level activities. The company was founded in 1991 and is headquartered in Boca Raton, FL.

DigitalBridge Group Inc - Ordinary Shares - Class A

DigitalBridge (DBRG) is trending due to reports confirming SoftBank's agreement to acquire the digital infrastructure firm for $16 per share, valuing it at approximately $4 billion. The community is actively debating if this offer undervalues DBRG, given its extensive digital asset portfolio and critical role in the accelerating AI infrastructure build-out, with many hoping for a higher bid.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas ($GASS) is trending amidst high community engagement, driven by optimistic calls for significant price appreciation and comparisons to $PEPE due to shared creator Matt Furie. Despite noted volatility and some skepticism, a strong contingent of holders are "loading up" and advocating a "HODL" strategy, believing in its potential for substantial future gains.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is at the forefront of market discussion after reporting compelling Phase 3 results for its ovarian cancer treatment, relacorilant, which demonstrated improved patient survival and progression-free outcomes. This positive data, along with an impending FDA decision for relacorilant in Cushing's syndrome, fuels intense community debate between those forecasting multi-billion dollar revenue and an epic short squeeze, and others citing recent price pullbacks and insider selling. The company's expanding pipeline of cortisol modulators positions it for significant future growth beyond its current therapeutic focus.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant selling pressure from SPAC-related dilution and year-end tax loss harvesting, fueling a highly polarized community debate. While optimists highlight the company's strong fundamentals and long-term growth potential similar to an early Robinhood, skeptics warn of continued price declines and negative technicals until the current overhang is resolved.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens (XLM) is trending amidst notable institutional activity, including its involvement in a new Blockchain Payments Consortium and U.S. Bank's exploration of stablecoin issuance on the network. The community is actively discussing XLM's role in advancing cross-border payments, alongside network upgrades and ongoing real-world payment integrations that underscore its growing utility and adoption in the digital finance landscape.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics (CADL) is trending as the community interprets executive stock option deferrals to 2026 as a strong signal of impending significant value appreciation or a corporate transaction. With compelling clinical data for its CAN-2409 program in high-value oncology indications and its current market capitalization, investors are anticipating potential partnerships or an acquisition ahead of key milestones next year.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. It operates through the following segments: dCELL, BioRinse, GBM-V, and Central. The dCELL segment technology platform removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold. The BioRinse segment offers sterile tissue prepared in a manner to minimise the negative effects of processing. The GBM-V segment is a regional tissue bank based in Rostock, Germany, which currently produces tissue preparations for ophthalmology. The company was founded by Eileen Ingham and John Fisher in May 2006 and is headquartered in Leeds, the United Kingdom.

TSSNF
Tissue Regenix Group Plc

Feed

News

Sentiment

Fundamentals

Info

Latest TSSNF News

TSSNFTissue Regenix Group Plc